A Small-Molecule TrkB Agonist Promotes Synaptic Resilience Against Aβ and Tau Oligomers and Mitigates Alterations in TrkB-Akt and Fyn Signaling
Cells · 2026
DOI: 10.3390/cells15191822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Tao Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-fyn, Amyloid beta-Peptides, tau Proteins, Receptor, trkB. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scully Initiative, Taube Family Foundation, Jean Perkins Foundation.
Abstract (Originalsprache)
Background
Pathogenic amyloid-beta and tau oligomers (oAβ, oTau) drive synaptic degeneration and cognitive decline in Alzheimer’s disease (AD). Tropomyosin receptor kinase B (TrkB), expressed in neurons and glia, supports synaptic integrity in AD-affected regions. We tested whether PTX-BD4-3, a small-molecule TrkB partial agonist, promotes neuroprotective signaling, reduces degenerative signaling, and prevents synaptic loss in an AD mouse model and hippocampal neurons exposed to oAβ or oTau.
Methods
Cultured hippocampal neurons were treated with oAβ or oTau ± PTX-BD4-3. Effects on synaptic proteins (±TrkB-blocking antibody), spine density, and Fyn, NR2B, and tau phosphorylation as well as tau oligomerization were assessed. Two cohorts of APPL/S mice, 5 and 12 months of age, received intraperitoneal PTX-BD4-3 or vehicle for 3 months, followed by assessment of synaptic proteins, dendritic spines, TrkB signaling, and Y-maze analysis.
Results
In vitro, PTX-BD4-3 prevented oAβ-induced synaptic marker loss in a TrkB-dependent manner, reduced phosphorylation of Fyn, NR2B, and tau, suppressed oligomeric tau formation, and attenuated oTau-induced spine loss. In APPL/S mice, PTX-BD4-3 mitigated deficient TrkB/Akt signaling, reduced phosphorylation of Fyn and tau, preserved synaptic markers and dendritic spines, and improved Y-maze performance.
Conclusions
Small-molecule TrkB partial agonists may normalize TrkB signaling and promote synaptic resilience, supporting their potential as AD therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA.
- Department of Neurology, San Francisco Veterans Affairs Health Care System, San Francisco, CA 94121, USA.
- Department of Neurology, University of California, San Francisco, CA 94121, USA.
- Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA 94305, USA.
ORCID-Profile: Tao Yang, Vanessa F Langness, Stephen M Massa, Frank M Longo
Förderung
- Scully Initiative
- Taube Family Foundation
- Jean Perkins Foundation
- Horngren Family
Zitieren
APA
Yang, T., Tran, K. C., Leng, A., Langness, V. F., Massa, S. M., & Longo, F. M. (2026). A Small-Molecule TrkB Agonist Promotes Synaptic Resilience Against Aβ and Tau Oligomers and Mitigates Alterations in TrkB-Akt and Fyn Signaling. Cells. https://doi.org/10.3390/cells15191822
Vancouver
Yang T, Tran KC, Leng A, Langness VF, Massa SM, Longo FM. A Small-Molecule TrkB Agonist Promotes Synaptic Resilience Against Aβ and Tau Oligomers and Mitigates Alterations in TrkB-Akt and Fyn Signaling. Cells. 2026. doi:10.3390/cells15191822
BibTeX
@article{Yang2026,
author = {Yang, Tao and Tran, Kevin C and Leng, Albert and Langness, Vanessa F and Massa, Stephen M and Longo, Frank M},
title = {A Small-Molecule TrkB Agonist Promotes Synaptic Resilience Against Aβ and Tau Oligomers and Mitigates Alterations in TrkB-Akt and Fyn Signaling},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15191822}
}
EUVIMED